Conditions: Psoriasis
Keywords: plaque psoriasis etanercept adalimumab
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 64
Healthy volunteers: no

Brief summary:
This study will evaluate the efficacy of etanercept in patients with plaque psoriasis who have lost a satisfactory response to adalimumab.

Detailed description:

Arms:
arm 1: Participants received etanercept 50 mg, twice weekly (BIW), subcutaneously (SC) for 12 weeks followed by 50 mg, once weekly (QW), SC for an additional 12 weeks.

Interventions: intervention 1: Etanercept
Intervention descriptions: intervention 1: Administered by subcutaneous injection

Protocol document: